4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Brii Biosciences Limited (2137) operates in the Biotechnology industry and is headquartered in Beijing, China with about 75 employees. Its market capitalization is roughly CNY 703 million. In the fiscal year ended 2025-12-31, 2137 reported CNY 19M in revenue and (CNY 223M) in net income.
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 19M | CNY 0M | CNY 1M | CNY 52M | — |
| Operating Income (EBIT) | (CNY 287M) | (CNY 353M) | (CNY 545M) | (CNY 514M) | — |
| Net Income | (CNY 223M) | (CNY 508M) | (CNY 175M) | (CNY 484M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 2.4B | CNY 2.7B | CNY 3.2B | CNY 3.4B | — |
| Total Liabilities | CNY 36M | CNY 100M | CNY 126M | CNY 234M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2137 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms